Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on Friday, July 31, 2026, at 10:00 a.m. Pacific Time. Stockholders will vote on the election of two Class II directors, the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2026, and an advisory vote on named executive officer compensation. The record date for voting is June 5, 2026, with 28,009,802 shares outstanding.

Jasper Therapeutics, Inc. received a notice from The Nasdaq Stock Market LLC on June 3, 2026, indicating non-compliance with the minimum $1.00 bid price requirement for continued listing. The company's voting common stock had closed below $1.00 per share for 30 consecutive business days. Jasper Therapeutics has an initial 180-calendar day period, until November 30, 2026, to regain compliance. The company intends to monitor its bid price and consider options, including a reverse stock split, if necessary.

Jasper Therapeutics, Inc. announced that its Board of Directors has initiated a comprehensive review of strategic alternatives to maximize shareholder value. Following an evaluation of current market conditions, the options being considered include a sale of assets, licensing, collaborations, a sale of the company, a business combination, merger, or an orderly wind-down of operations. The company also plans to evaluate cost-saving measures to preserve cash and maintain regulatory compliance, though there is no defined timeline or assurance of a specific outcome from this process.

Jasper Therapeutics' Board of Directors has initiated a comprehensive review of strategic alternatives to maximize shareholder value. Options under consideration include a sale or licensing of assets, collaborations, a company sale, business combination, merger, or an orderly wind-down of operations. The clinical-stage biotechnology company, focused on developing briquilimab for mast cell driven diseases, will also evaluate cost-saving measures and maintain regulatory compliance during this process. There is no defined timeline, and no assurance that the process will result in any specific action or maximize stockholder value.

Jasper Therapeutics, Inc. announced that Christian Nolet resigned from its Board of Directors and all associated committees, effective May 15, 2026. The company stated that his departure was not due to any disagreement regarding company operations or policies. Concurrently, the Board appointed Svetlana Lucas, Ph.D. as a new member of its Audit Committee.

Jasper Therapeutics, a clinical-stage biotechnology company, reported a significantly reduced net loss of $1.2 million for Q1 2026, down from $21.2 million in Q1 2025. This improvement was primarily driven by a $9.6 million non-cash gain from the change in fair value of warrant liability and reduced operating expenses. However, the company issued a going concern warning, stating that its $14.1 million cash and cash equivalents as of March 31, 2026, are insufficient to fund operations for the next twelve months, and it is actively seeking additional capital.

Jasper Therapeutics, Inc. reported a net loss of $1.2 million for the first quarter ended March 31, 2026, with cash and cash equivalents totaling $14.1 million. The company provided a corporate update, including the appointment of Jeet Mahal as Chief Executive Officer and the refiling of an updated Phase 2b protocol with the FDA for briquilimab in chronic spontaneous urticaria (CSU). Jasper also highlighted positive updated data from its briquilimab studies in CSU from January 2026, showing high response rates, and plans to commence the Phase 2b study in the second half of 2026, pending additional funding.

Jasper Therapeutics, Inc. filed an amendment to its Form 10-K, restating Part III and amending Item 15 of Part IV. This amendment provides updated information on the company's corporate governance, including its executive officers and directors, their compensation, and board committee structures. Key leadership changes include Jeet Mahal's appointment as President and CEO, and Tom Wiggans' appointment as Executive Chairperson, both effective January 2026.